Not vested
Valuations and risks:
JM/JS are trading near their respective historicalaverages, but they still represent cheaper alternatives to directly investing in their relatively more expensive subsidiaries.
After MTM its listed subsidiaries since our last update (May 2011), NAV for JM/JS has risen by 5%/6% to $74.9/$53.9 (from $71.6/$50.8).
Based on historical average discounts of 20%/39% for JM/JS and rolling over to Dec-11, our PTs for JM/JS have accordingly been raised by 5%/6% to $60/$33.
A key upside risk is unexpected group restructuring. Key downside risks are unfavourable currency movements and liquidity tightening in Asia.
Source: JPM